Immunotherapy plus targeted medicine with TACE around liver surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial tests whether combining camrelizumab and apatinib with TACE before/around liver cancer surgery can improve outcomes for people with certain stages of hepatocellular carcinoma (HCC). It may help by strengthening the immune attack on cancer and by blocking blood supply to tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing to sign consent and join the study.
- You’re age 18 or older.
- Your liver cancer (hepatocellular carcinoma) must be confirmed by biopsy/cytology or imaging.
- Your cancer stage must match CNLC Ib, IIa, IIb, or IIIa (with specific exceptions), and you may need surgery and/or TACE as part of the plan.
- Your liver health must be good enough: Child-Pugh A (score 6 or less).
- Your overall health walking ability must be ECOG 0–1 (able to do most usual activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This study tests two different treatment combinations for liver cancer that cannot be removed with surgery. One group gets a treatment called TACE plus a pill combination, and the other gets TACE plus standard targeted immunotherapy. The goal is to see which approach works better.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
This study looks at how well a combination of camrelizumab and apatinib works for people with unresectable hepatocellular carcinoma (liver cancer you can’t remove with surgery). It is designed to see results in real-life care for patients who have limited options after standard treatment.
This study tests a personalized combination treatment for unresectable (cannot be removed with surgery) liver cancer. It uses a special test to guide which drugs you receive, aiming to improve how well the treatment works for your specific tumor type.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.